SG11201807255YA - Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones - Google Patents
Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormonesInfo
- Publication number
- SG11201807255YA SG11201807255YA SG11201807255YA SG11201807255YA SG11201807255YA SG 11201807255Y A SG11201807255Y A SG 11201807255YA SG 11201807255Y A SG11201807255Y A SG 11201807255YA SG 11201807255Y A SG11201807255Y A SG 11201807255YA SG 11201807255Y A SG11201807255Y A SG 11201807255YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- autoimmune diseases
- corrizo
- pct
- capistrano
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 3
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000005495 thyroid hormone Substances 0.000 title abstract 2
- 229940036555 thyroid hormone Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940121908 Retinoid X receptor agonist Drugs 0.000 abstract 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11M11111011101010111110101111 1011101111011101110011101111111110111011 International Bureau .. .... ..Yejd (10) International Publication Number ..... .....1 (43) International Publication Date WO 2017/155577 Al 14 September 2017 (14.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every (21) (22) (25) A61K 45/06 (2006.01) C07C 57/30 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 37/00 (2006.01) CO7C 57/50 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, CO7C 57/03 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US2016/059772 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 31 October 2016 (31.10.2016) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every (71) (72) 62/306,479 10 March 2016 (10.03.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Applicant: I0 THERAPEUTICS, INC. [US/US]; 26242 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Via Corrizo, San Juan Capistrano, CA 92675 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Inventors: CHANDRARATNA, Roshantha, A.; 26242 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Via Corrizo, San Juan Capistrano, CA 92675 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SANDERS, Martin, E.; 26242 Via Corrizo, San Juan SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Capistrano, CA 92675 (US). GW, KM, ML, MR, NE, SN, TD, TG). Agents: CULLMAN, Louis, C. et al.; K&L GATES LLP, Published: (74) 1 Park Plaza, 12th Floor, Irvine, CA 92614 (US). — with international search report (Art. 21(3)) Title: TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID (54) HORMONES FIG. 1 100 . \" RXRIi 7 . 50 x l t0 .. t 2 5 .' 1-1 Q IN ilibtimegi IN kl) kl) kl) le 104 10.7 ,-1 it-- Concentration (nM ) N (57) : The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662306479P | 2016-03-10 | 2016-03-10 | |
PCT/US2016/059772 WO2017155577A1 (en) | 2016-03-10 | 2016-10-31 | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807255YA true SG11201807255YA (en) | 2018-09-27 |
Family
ID=59790734
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807255YA SG11201807255YA (en) | 2016-03-10 | 2016-10-31 | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
Country Status (16)
Country | Link |
---|---|
US (4) | US10946001B2 (en) |
EP (2) | EP4166160A1 (en) |
JP (1) | JP7169646B2 (en) |
KR (4) | KR102222619B1 (en) |
CN (6) | CN109310769B (en) |
AU (1) | AU2016396658B2 (en) |
CA (1) | CA3016876C (en) |
DK (1) | DK3426302T3 (en) |
ES (1) | ES2940239T3 (en) |
IL (4) | IL261669B2 (en) |
MX (2) | MX2018010862A (en) |
NZ (1) | NZ745703A (en) |
PL (1) | PL3426302T3 (en) |
SG (1) | SG11201807255YA (en) |
WO (1) | WO2017155577A1 (en) |
ZA (1) | ZA201805941B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0616454A2 (en) | 2005-09-30 | 2011-06-21 | Vitae Pharmaceuticals Inc | cancer treatment methods |
US20130190395A1 (en) | 2011-12-13 | 2013-07-25 | Dartmouth College | Autoimmune disorder treatment using rxr agonists |
KR102489706B1 (en) | 2015-10-31 | 2023-01-17 | 아이오 테라퓨틱스, 인크. | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones |
JP7169647B2 (en) | 2016-03-10 | 2022-11-11 | アイオー セラピューティクス インコーポレイテッド | Treatment of muscle disorders with a combination of RXR agonists and thyroid hormones |
CA3016876C (en) | 2016-03-10 | 2021-12-28 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
AU2018335393A1 (en) * | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
CA3082485A1 (en) | 2017-11-17 | 2019-05-23 | Io Therapeutics, Inc. | Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
US11896558B2 (en) | 2021-12-07 | 2024-02-13 | Io Therapeutics, Inc. | Use of an RXR agonist and taxanes in treating Her2+ cancers |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4756911A (en) | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
EP0671005A1 (en) | 1992-11-25 | 1995-09-13 | La Jolla Cancer Research Foundation | Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression |
US5466861A (en) | 1992-11-25 | 1995-11-14 | Sri International | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors |
KR0126300B1 (en) | 1992-12-28 | 1997-12-26 | 나이토 하루오 | Heterocyclic carbonic acid derivatives which bind to retinoid receptors |
US5455265A (en) | 1993-02-11 | 1995-10-03 | Allergan, Inc. | Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
US5675033A (en) | 1995-06-06 | 1997-10-07 | Allergan | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
US5917082A (en) | 1995-06-06 | 1999-06-29 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having retinoid-like biological activity |
JP3964478B2 (en) | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same |
US6218128B1 (en) | 1997-09-12 | 2001-04-17 | Allergan Sales, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US6008204A (en) | 1995-09-01 | 1999-12-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5776699A (en) | 1995-09-01 | 1998-07-07 | Allergan, Inc. | Method of identifying negative hormone and/or antagonist activities |
US5958954A (en) | 1995-09-01 | 1999-09-28 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6942980B1 (en) | 1995-09-01 | 2005-09-13 | Allergan, Inc. | Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities |
US5952345A (en) | 1995-09-01 | 1999-09-14 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US5675024A (en) | 1995-11-22 | 1997-10-07 | Allergan | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity |
US5965606A (en) | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
US5877207A (en) | 1996-03-11 | 1999-03-02 | Allergan Sales, Inc. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US20030219832A1 (en) | 1996-03-11 | 2003-11-27 | Klein Elliott S. | Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
US5763635A (en) | 1996-06-21 | 1998-06-09 | Allergan | Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity |
US6555690B2 (en) | 1996-06-21 | 2003-04-29 | Allergan, Inc. | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5773594A (en) | 1996-06-21 | 1998-06-30 | Allergan | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
US5739338A (en) | 1996-11-05 | 1998-04-14 | Allergan | N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity |
DE69726182T2 (en) | 1996-12-11 | 2004-08-12 | Dana-Farber Cancer Institute, Inc., Boston | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR GROWTH PREVENTION OF TUMOR CELLS CONTAINING A PPAR-GAMMA AGONIST AND A MAP KINASE INHIBITOR |
US5728846A (en) | 1996-12-12 | 1998-03-17 | Allergan | Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
US6037488A (en) | 1997-04-19 | 2000-03-14 | Allergan Sales, Inc. | Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6063768A (en) | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
AU3595099A (en) | 1998-05-11 | 1999-11-29 | Novo Nordisk A/S | New compounds, their preparation and use |
WO1999063980A1 (en) | 1998-06-12 | 1999-12-16 | Ligand Pharmaceuticals Inc. | Treatment of anti-estrogen resistant breast cancer using rxr modulators |
US6048873A (en) | 1998-10-01 | 2000-04-11 | Allergan Sales, Inc. | Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity |
US6403638B1 (en) | 1998-10-01 | 2002-06-11 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US6147224A (en) | 1998-10-01 | 2000-11-14 | Allergan Sales, Inc. | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
US6521641B1 (en) | 1998-10-08 | 2003-02-18 | Allergan, Inc. | Male anti-fertility agents |
US6776984B1 (en) | 1999-08-20 | 2004-08-17 | George R. Schwartz | Induced regeneration and repair of damaged neurons and nerve axon myelin |
US6043381A (en) | 1999-05-07 | 2000-03-28 | Allergan Sales, Inc. | Process for preparing substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo[1,2-g]-1,2-dihydroquinoline derivatives |
WO2001007028A2 (en) | 1999-07-23 | 2001-02-01 | Allergan Sales, Inc. | The use of retinoid receptor antagonists in the treatment of prostate carcinoma |
US6187750B1 (en) | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
AU7586600A (en) | 1999-09-14 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Rxr modulators with improved pharmacologic profile |
US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
TWI281911B (en) | 2000-04-04 | 2007-06-01 | Allergan Inc | Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents |
US20030077664A1 (en) | 2001-04-18 | 2003-04-24 | Yi Zhao | Methods of screening for compounds that modulate hormone receptor activity |
US20020193403A1 (en) | 2001-05-03 | 2002-12-19 | Allergan Sales, Inc. | Methods of treating hyperlipidemia |
CA2449166A1 (en) | 2001-05-08 | 2002-11-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using anti-egfr antibodies and anti-hormonal agents |
GB0111314D0 (en) * | 2001-05-09 | 2001-07-04 | Karobio Ab | Dermatological formulations |
JP2005511516A (en) | 2001-09-25 | 2005-04-28 | スミスクライン ビーチャム コーポレーション | Selective RXR ligand |
US6645526B2 (en) | 2001-11-13 | 2003-11-11 | Mylan Pharmaceuticals, Inc. | Storage stable thyroxine active drug formulations and methods for their production |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003078567A2 (en) | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
US6720423B2 (en) | 2002-04-30 | 2004-04-13 | Allergan, Inc. | Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors |
RU2004138294A (en) | 2002-06-04 | 2005-06-10 | Галдерма Ресерч Энд Девелопмент, С.Н.С. (Fr) | NEW LIGANDS AS RAR RECEPTOR INHIBITORS, METHOD FOR PRODUCING THEM AND THEIR APPLICATION FOR TREATMENT OF HUMAN AND IN MEDICAL COSMETICS |
US20040005304A1 (en) | 2002-07-08 | 2004-01-08 | Mak Wood, Inc. | Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions |
JP4275365B2 (en) | 2002-08-06 | 2009-06-10 | 三菱電機株式会社 | Combined gas insulated switchgear |
US7105566B2 (en) | 2002-10-22 | 2006-09-12 | Allergan, Inc. | Methods of treatment during vascular procedures |
DE60312548T2 (en) | 2002-11-18 | 2007-12-13 | Galderma Research & Development, S.N.C. | NEW LIGANDS WHICH ARE ANTAGONISTS OF RAR RECEPTORS, METHODS OF MANUFACTURING SUCH LIGANDS, AND THE USE OF THESE LIGANDS IN HUMAN MEDICINE AND COSMETICS |
US7019034B2 (en) | 2003-01-28 | 2006-03-28 | Allergan, Inc. | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals |
US6936636B2 (en) | 2003-06-26 | 2005-08-30 | Allergan, Inc. | 5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity |
AU2004263156B2 (en) * | 2003-08-07 | 2009-02-26 | Allergan, Inc. | Method for treating cachexia with retinoid ligands |
US7785632B2 (en) | 2003-09-15 | 2010-08-31 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
WO2005046726A2 (en) | 2003-11-12 | 2005-05-26 | Allergan, Inc. | Combinations for inhibiting cell growth which contains an inhibitor of human ck1 alpha activity and a rxr agonist |
AU2005209201B2 (en) | 2004-01-20 | 2010-06-03 | Allergan, Inc. | Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
EP1799812A4 (en) | 2004-09-16 | 2009-09-09 | Gamida Cell Ltd | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
US8105611B2 (en) | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
EP1933825A2 (en) * | 2005-08-18 | 2008-06-25 | Merck and Co., Inc. | Combination methods of saha and targretin for treating cancer |
BRPI0616454A2 (en) | 2005-09-30 | 2011-06-21 | Vitae Pharmaceuticals Inc | cancer treatment methods |
EP1937640A2 (en) | 2005-09-30 | 2008-07-02 | Janssen Pharmaceutica N.V. | 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
JP2009513570A (en) | 2005-09-30 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Heterocyclic amide derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
JP2009512637A (en) * | 2005-09-30 | 2009-03-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Dihydro- [1H] -quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
US20070185055A1 (en) | 2006-02-06 | 2007-08-09 | Guang Liang Jiang | Method for treating cachexia with retinoid ligands |
CN1806798A (en) * | 2006-02-23 | 2006-07-26 | 北京阜康仁生物制药科技有限公司 | Medicinal composition making bexarotene as active ingredients, its preparation method and use |
CN101674842A (en) | 2007-03-02 | 2010-03-17 | 普瑞芬医药有限公司 | Compositions and methods for treating alzheimer's disease and dementia |
US20090136470A1 (en) | 2007-06-13 | 2009-05-28 | Hilde Cheroutre | Regulatory t cells and methods of making and using same |
WO2009102789A2 (en) | 2008-02-15 | 2009-08-20 | Wyeth | Use of rxr agonists for the treatment of osteroarthritis |
ES2332169B1 (en) | 2008-07-24 | 2010-10-25 | Universidad Del Pais Vasco | EMPLOYMENT OF MICROPARTICLES THAT INCLUDE GENETICALLY MODIFIED CELLS IN THE TREATMENT OF NEURODEGENERATIVE DISEASES. |
EP2344677B1 (en) | 2008-10-08 | 2017-04-05 | Cambridge Enterprise Limited | Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis |
WO2010041449A1 (en) | 2008-10-09 | 2010-04-15 | 国立大学法人 岡山大学 | Anti-allergic agent comprising rxr agonist as active ingredient |
US20110008437A1 (en) | 2009-04-20 | 2011-01-13 | Altman Gregory H | Silk Fibroin Hydrogels and Uses Thereof |
US20100292281A1 (en) | 2009-05-15 | 2010-11-18 | The University Of Kentucky Research Foundation | Treatment of mci and alzheimer's disease |
US20100298434A1 (en) | 2009-05-21 | 2010-11-25 | Claude Rouillard | Neuroprotection and prevention of dopaminergic cell death by targeting nur77 translocation |
JP2010280585A (en) | 2009-06-02 | 2010-12-16 | Okayama Univ | Analgesic comprising rxr agonist as active ingredient |
EP2451455A4 (en) | 2009-07-10 | 2013-01-16 | Univ Case Western Reserve | Rxr agonist compounds and methods |
AU2011218019B2 (en) | 2010-02-19 | 2016-03-24 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Novel bexarotene analogs |
WO2012125749A2 (en) | 2011-03-14 | 2012-09-20 | Io Therapeutics, Inc. | INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS |
EP2556827A1 (en) * | 2011-08-11 | 2013-02-13 | Acadia Pharmaceuticals Inc. | Treatment of neurodegenerative diseases |
EP2766018A4 (en) | 2011-10-13 | 2015-02-25 | Univ Case Western Reserve | Rxr agonists compounds and methods |
US10653650B2 (en) * | 2011-12-13 | 2020-05-19 | Io Therapeutics, Inc. | Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists |
US20130190395A1 (en) | 2011-12-13 | 2013-07-25 | Dartmouth College | Autoimmune disorder treatment using rxr agonists |
US9446105B2 (en) | 2013-03-15 | 2016-09-20 | The Trustees Of The University Of Pennsylvania | Chimeric antigen receptor specific for folate receptor β |
WO2015059632A1 (en) | 2013-10-23 | 2015-04-30 | Acadia Pharmaceuticals Inc. | Treatment of a neurodegenerative disease or disorder |
EP3063267A4 (en) | 2013-10-29 | 2017-10-18 | Vestion Inc. | Cardiac neural crest cells and methods of use thereof |
JP2018512396A (en) | 2015-03-09 | 2018-05-17 | キングス・カレッジ・ロンドン | Combination therapy with RAR alpha agonists to enhance TH1 response |
KR102489706B1 (en) | 2015-10-31 | 2023-01-17 | 아이오 테라퓨틱스, 인크. | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones |
EP3368081A4 (en) | 2015-10-31 | 2019-06-19 | IO Therapeutics, Inc. | Treatment of cancer with combinations of rxr agonists and thyroid hormones |
US20180318241A1 (en) | 2015-10-31 | 2018-11-08 | Io Therapeutics, Inc. | Treatment of nervous system disorders using thyroid hormone neutral doses of rxr agonists |
CA3016876C (en) | 2016-03-10 | 2021-12-28 | Io Therapeutics, Inc. | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones |
JP7169647B2 (en) | 2016-03-10 | 2022-11-11 | アイオー セラピューティクス インコーポレイテッド | Treatment of muscle disorders with a combination of RXR agonists and thyroid hormones |
CN106983738B (en) * | 2017-04-13 | 2020-03-10 | 深圳市润佳通科技有限公司 | Application of thyroid hormone and pharmaceutically acceptable salt or prodrug thereof in preparation of medicines for treating and/or preventing skin diseases |
AU2018326617B2 (en) | 2017-08-31 | 2022-12-01 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
AU2018335393A1 (en) | 2017-09-20 | 2020-04-02 | Io Therapeutics, Inc. | Treatment of disease with esters of selective RXR agonists |
CA3082485A1 (en) | 2017-11-17 | 2019-05-23 | Io Therapeutics, Inc. | Compounds and synthetic methods for the preparation of retinoid x receptor-specific retinoids |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
-
2016
- 2016-10-31 CA CA3016876A patent/CA3016876C/en active Active
- 2016-10-31 IL IL261669A patent/IL261669B2/en unknown
- 2016-10-31 US US16/083,799 patent/US10946001B2/en active Active
- 2016-10-31 CN CN201680085544.XA patent/CN109310769B/en active Active
- 2016-10-31 PL PL16893789.4T patent/PL3426302T3/en unknown
- 2016-10-31 EP EP22212924.9A patent/EP4166160A1/en active Pending
- 2016-10-31 CN CN202210685748.4A patent/CN114904000A/en active Pending
- 2016-10-31 DK DK16893789.4T patent/DK3426302T3/en active
- 2016-10-31 JP JP2018547277A patent/JP7169646B2/en active Active
- 2016-10-31 KR KR1020187029177A patent/KR102222619B1/en active Application Filing
- 2016-10-31 WO PCT/US2016/059772 patent/WO2017155577A1/en active Application Filing
- 2016-10-31 CN CN202210686511.8A patent/CN115252789A/en active Pending
- 2016-10-31 KR KR1020237039730A patent/KR20230164204A/en active Search and Examination
- 2016-10-31 KR KR1020217005469A patent/KR102549273B1/en active IP Right Grant
- 2016-10-31 ES ES16893789T patent/ES2940239T3/en active Active
- 2016-10-31 MX MX2018010862A patent/MX2018010862A/en unknown
- 2016-10-31 NZ NZ74570316A patent/NZ745703A/en unknown
- 2016-10-31 SG SG11201807255YA patent/SG11201807255YA/en unknown
- 2016-10-31 CN CN202111563134.0A patent/CN114470218A/en active Pending
- 2016-10-31 CN CN202210686499.0A patent/CN115227825A/en active Pending
- 2016-10-31 EP EP16893789.4A patent/EP3426302B1/en active Active
- 2016-10-31 CN CN202210686539.1A patent/CN115227826A/en active Pending
- 2016-10-31 AU AU2016396658A patent/AU2016396658B2/en active Active
- 2016-10-31 KR KR1020227004910A patent/KR102605349B1/en active IP Right Grant
-
2018
- 2018-09-05 ZA ZA2018/05941A patent/ZA201805941B/en unknown
- 2018-09-07 MX MX2021011785A patent/MX2021011785A/en unknown
-
2021
- 2021-01-15 US US17/150,646 patent/US11690831B2/en active Active
-
2022
- 2022-01-26 US US17/585,349 patent/US11690832B2/en active Active
-
2023
- 2023-05-19 US US18/320,762 patent/US20230293506A1/en active Pending
- 2023-07-19 IL IL304576A patent/IL304576A/en unknown
- 2023-07-19 IL IL304578A patent/IL304578A/en unknown
- 2023-07-19 IL IL304577A patent/IL304577A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807255YA (en) | Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones | |
SG11201807250PA (en) | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones | |
SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201901548SA (en) | Anti-tim-3 antibodies and use thereof | |
SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201805072PA (en) | Nicotine powder delivery system | |
SG11201908092RA (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11202000263QA (en) | Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201805755SA (en) | Methods of administering hepcidin | |
SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
SG11201807915QA (en) | Differentiation of pluripotent stem cells to intestinal midgut endoderm cells |